Table 5.

Survival outcomes by FcγRIIa and FcγRIIIa polymorphisms and treatment in RAS-mutant versus RAS wild-type patients and TP53-mutant versus TP53 wild-type patients

FcγR polymorphismBiomarker status5-y PFS (95% CI)Treatment by FcγR SNP interaction5-y DPFS (95% CI)Treatment by FcγR SNP interaction5-y OS (95% CI)Treatment by FcγR SNP interaction
CAPOXCAPOX-CPCAPOXCAPOX-CPCAPOXCAPOX-CP
HH and/or VVR and FRAS mutant (n = 46)44.4 (11.9–76.9)0 (0–0)0.07166.7 (29.1–100)0 (0–0)0.10855.6 (23.1–88.1)50.0 (0–100)0.349
58.2 (32.5–83.9)70.6 (48.8–92.3)74.3 (48.8–99.8)70.8 (49.0–92.6)57.8 (31.9–83.7)81.9 (63.3–100)
HH and/or VVR and FRAS wild-type (n = 52)71.4 (37.9–100)50.0 (10.0–89.9)0.06483.3 (53.5–100)50.0 (10.0–89.9)0.07671.4 (37.9–100)66.7 (29.1–100)0.182
55.0 (32.9–77.1)84.2 (67.7–100)68.6 (47.8–89.4)84.2 (67.7–100)60.0 (38.4–81.6)89.5 (75.8–100)
HH and/or VVR and FTP53 mutant (n = 49)50.0 (10.0–90.0)14.3 (0–40.2)0.07080.0 (44.9–100)17.1 (0–47.7)0.05950.0 (10.0–90.0)42.9 (6.2–79.6)0.281
47.6 (21.9–73.3)63.2 (41.4–84.9)54.7 (27.3–82.1)63.2 (41.4–84.9)54.2 (29.1–79.3)78.9 (60.5–97.3)
HH and/or VVR and FTP53 wild-type (n = 45)60.0 (29.6–90.4)66.7 (13.4–100)0.32275.0 (45.0–100)66.7 (13.4–100)0.38270.0 (41.6–98.4)100 (100–100)0.987
53.5 (29.4–77.6)92.9 (79.4–100)81.6 (62.8–100)92.9 (79.4–100)61.1 (38.6–83.6)93.3 (80.0–100)